A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension
| Status: | Completed |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), Ocular |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 4/17/2018 |
| Start Date: | May 2014 |
| End Date: | August 2017 |
A Phase 1/2 Multicenter, Randomized, Controlled Dose-Finding Study to Evaluate the Safety and Ocular Hypotensive Efficacy of 3 Dose Levels of the VS101 Subconjunctival Latanoprost Insert for 3 Months in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy
with topically administration of commercially available latanoprost in patient with glaucoma
and ocular hypertension
with topically administration of commercially available latanoprost in patient with glaucoma
and ocular hypertension
Inclusion Criteria:
- Age > 18
- Open angle glaucoma or Ocular Hypertension
Exclusion Criteria:
- uncontrolled medical conditions
- wearing of contact lenses
We found this trial at
1
site
Click here to add this to my saved trials
